Hepatic and splenic venous access tract closure using the VASCADE vascular closure system following percutaneous intervention in patients with CHD
Cardiology in the Young · 2024
DOI: 10.1017/s1047951124025538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology in the Young, 2024. Verfasst von Lindsay F Eilers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Charles E. Mullins Cardiac Catheterization Laboratories, Texas Children's Hospital, and Lillie Frank Abercrombie Section of Cardiology, Department of…. Hauptthemen laut MEDLINE: Cardiac Catheterization, Splenic Vein, Vascular Closure Devices, Hepatic Veins.
Abstract (Originalsprache)
Background
Hepatic and splenic venous access are specialised techniques used to perform diagnostic and interventional procedures in the cardiac catheterisation laboratory. Bleeding events are the most commonly reported complication following hepatic or splenic venous access. The VASCADE Vascular Closure System (Cardiva Medical Inc. Santa Barbara, CA) is an approved device for closure of femoral vascular access tracts in patients ≥18 years of age. We report our experience using VASCADE to close the hepatic or splenic venous access site in the cardiac catheterisation laboratory.
Methods
This is a single centre retrospective review of all patients who had percutaneous hepatic or splenic venous access obtained in the cardiac catheterisation laboratory from March 1, 2022 through October 30, 2023 and underwent tract closure with VASCADE.
Results
Ten patients (six male) underwent 16 procedures (median age and weight 3.5 years and 12.5 kg) with 15 hepatic and two splenic veins accessed. Successful closure of the access tracts with VASCADE was performed in all patients. There were no major adverse events related to closure of the access sites with VASCADE.
Conclusion
VASCADE can be used following transhepatic and trans-splenic venous access in the cardiac catheterisation laboratory to safely close the access tract and potentially reduce the risk of post-procedural bleeding complications. Further evaluation in a larger cohort of patients is needed to ensure VASCADE is safe for use and provides adequate haemostasis following hepatic or splenic venous access, particularly in children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Charles E. Mullins Cardiac Catheterization Laboratories, Texas Children's Hospital, and Lillie Frank Abercrombie Section of Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
ORCID-Profile: Gary E Stapleton
Zitieren
APA
Eilers, L. F., Bansal, M., Khan, A., Webb, M. K., Qureshi, A. M., Gowda, S. T., & Stapleton, G. E. (2024). Hepatic and splenic venous access tract closure using the VASCADE vascular closure system following percutaneous intervention in patients with CHD. Cardiology in the Young. https://doi.org/10.1017/s1047951124025538
Vancouver
Eilers LF, Bansal M, Khan A, Webb MK, Qureshi AM, Gowda ST, et al. Hepatic and splenic venous access tract closure using the VASCADE vascular closure system following percutaneous intervention in patients with CHD. Cardiology in the Young. 2024. doi:10.1017/s1047951124025538
BibTeX
@article{Eilers2024,
author = {Eilers, Lindsay F and Bansal, Manish and Khan, Asra and Webb, Melissa K and Qureshi, Athar M and Gowda, Srinath T and Stapleton, Gary E},
title = {Hepatic and splenic venous access tract closure using the VASCADE vascular closure system following percutaneous intervention in patients with CHD},
journal = {Cardiology in the Young},
year = {2024},
doi = {10.1017/s1047951124025538}
}
EUVIMED